Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

The launch of UpSpring Stomach Settle Drops is causing an uproar as this revolutionary product is reversing the GLP1 side ...

Glaucoma Treatment MarketThe global glaucoma treatment market, valued at USD 5.7 billion in 2022, is projected to grow at a ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

As a retina specialist, one of the most important aspects of eye care I focus on is the prevention and treatment of diabetic retinopathy. This condition is a leading cause of blindness in adults, yet ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.